Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Príomhchruthaitheoirí: | Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
Interna Publishing
2017-04-01
|
Sraith: | Acta Medica Indonesiana |
Ábhair: | |
Rochtain ar líne: | http://www.actamedindones.org/index.php/ijim/article/view/327 |
Míreanna comhchosúla
Míreanna comhchosúla
-
Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
de réir: Jacqueline Mui Lan Lai, et al.
Foilsithe / Cruthaithe: (2019-01-01) -
Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
de réir: Hui Zhu, et al.
Foilsithe / Cruthaithe: (2015-01-01) -
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
de réir: Jiun-Ting Wu, et al.
Foilsithe / Cruthaithe: (2015-06-01) -
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
de réir: Vanessa Albertina Agertt, et al. -
Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
de réir: EVA SARTIKA DASOPANG, et al.
Foilsithe / Cruthaithe: (2020-02-01)